Startseite Forschung Publikationen


Adler S Huscher D, Siegert E, Allanore Y, Czirjak L, DelGaldo F, Denton CP, Distler O, Frerix M, Matucci-Cerinic M, Mueller-Ladner U, Tarner IH, Valentini G, Walker UA, Villiger PM, Riemekasten G.,

Systemic sclerosis associated interstitial lung disease – individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.

Arthritis Res Ther. 2018 ;20(1):17. Open Access London, UK : Current Science
Albrecht K Luque Ramos A, Callhoff J, Hoffmann F, Minden K, Zink A.,

Ambulante Versorgung und Krankheitslast der rheumatoiden Arthritis : Eine Analyse von Abrechnungsdaten und einer Versichertenbefragung. [Outpatient care and disease burden of rheumatoid arthritis : Results of a linkage of claims data and a survey of insured persons].

Z Rheumatol. 2018 ;77(2):102-112. Springer
Albrecht K Luque Ramos A, Hoffmann F, Redeker I, Zink A.,

High prevalence of diabetes in patients with rheumatoid arthritis: results from a questionnaire survey linked to claims data.

Rheumatology (Oxford). 2018 ;57(2):329-336.
Albrecht K Huscher D, Buttgereit F, Aringer M, Hoese G, Ochs W, Thiele K, Zink A.,

Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.

Rheumatol Int. 2018 ;38(4):569-577.
Albrecht K Zink A.,

Versorgungssituation der rheumatoiden Arthritis in Deutschland [The Situation of Rheumatoid Arthritis Care in Germany]

Akt Rheumatol. 2018 [epub ahead of print] Stuttgart Thieme
Alexander T Cheng Q, Klotsche J, Khodadadi L, Waka A, Biesen R, Hoyer BF, Burmester GR, Radbruch A, Hiepe F.,

Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors.

Eur J Immunol. 2018 ;48(9):1573-1579.
Aringer M Dörner T.,

Systemischer Lupus erythematodes (SLE) – neue Klassifikationskriterien. [Systemic Lupus Erythematosus (SLE) – New Classification Criteria].

Dtsch Med Wochenschr. 2018 ;143(11):811-814.
Arnold MB Khanna D, Denton CP, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE, Pope JE.,

Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.

Rheumatology (Oxford). 2018 ;57(1):152-157.
Arthur VL Shuldiner E, Remmers EF, Hinks A, Grom AA, Foell D, Martini A, Gattorno M, Ozen S, Prahalad S, Zeft AS, Bohnsack JF, Ilowite NT, Mellins ED, Russo R, Len C, Oliveira S, Yeung RSM, Rosenberg AM, Wedderburn LR, Anton J, Haas JP, Rosen-Wolff A, Minden K, Szymanski AM, Thomson W, Kastner DL, Woo P, Ombrello MJ.,

IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis.

Arthritis Rheumatol. 2018 ;70(8):1319-1330.
Babic M Romagnani C.,

Boosting Type 2 Immunity: When OX40L Comes from ILC2s.

Immunity. 2018 ;48(6):1067-1069.